A groundbreaking experimental treatment, designed to reset a malfunctioning immune system, has successfully put the autoimmune disease lupus into remission for several patients in early UK trials. Experts suggest this innovative approach could potentially offer a new avenue for treating other similar disorders, including multiple sclerosis and rheumatoid arthritis.
One of the first patients to undergo the treatment, Katie Tinkler, who was diagnosed 30 years ago, described her current health as having "never been this good." Previously struggling with severe symptoms that impacted her mobility and organ function, Ms Tinkler can now ski and no longer requires medication for her lupus. The disease, which affects approximately 50,000 individuals in the UK, causes the immune system to mistakenly attack the body's own tissues and organs, leading to symptoms like joint pain, skin conditions, and damage to vital organs such as the kidneys.
Lupus disproportionately affects women, accounting for 90% of cases in the UK, with diagnoses typically occurring in young adulthood. Ms Tinkler's condition had become increasingly aggressive over the past decade, leading to frequent hospital stays and damage to her heart, lungs, and kidneys, placing her at risk of needing dialysis. The experimental treatment, administered at University College London Hospitals, involves a complex process where millions of a patient's own T-cells are genetically modified in a laboratory to target and destroy the rogue B-cells responsible for producing antibodies that attack the body. These modified T-cells are then reintroduced into the patient.
Following the destruction of both rogue and healthy B-cells, the immune system is effectively 'reset' as new, healthy B-cells grow back months later. The process, which also involved chemotherapy to prevent the rejection of the modified T-cells, carries significant risks. However, Ms Tinkler, who received the treatment in November 2024, remains well, medication-free, and has seen a recovery in her organ function, stating, "I can live to an old lady with these kidneys and that is phenomenal."
Of the initial six patients treated, five are currently in remission, with one experiencing improved symptoms but a lupus flare after 11 months. Data presented by the research team at the EULAR European Congress of Rheumatology indicates that patients have remained well for over 18 months post-treatment. While these early results are highly encouraging, researchers caution that it is still uncertain how long the remission will last and how successful the treatment will prove to be when trialled in a larger patient cohort.
Dr Maria Leandro, a consultant rheumatologist at UCLH, highlighted the potential impact, stating that if patients could achieve consistent remission for three to five years, it would represent a significant advancement in lupus treatment, potentially even longer. The long-term efficacy and safety will be crucial in determining the broader application of this innovative therapy.
Source: BBC News